Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic with antibody through linker. the targeting characteristics traditional cytotoxic small molecule drugs, while reducing side effects both making them kind “biological missile” and representing relatively evolving anti-cancer drugs. Antibody-coupled currently used in many solid tumors, this article reviews clinic...

background: androgen receptors (ar) play an important role in proliferation of cancerous prostatic cells and prevention of apoptotic signaling. current drugs cannot inhibit the activity of these receptors very well. establishment of appropriate animal models is essential for discovery of new drugs of target therapy in hormone dependent prostate cancer. materials and methods: standard prostatic ...

Madam, Melanoma, the most lethal skin cancer, accounts for 75% of deaths by cancer in US.1 Nivolumab, Pembrolizumab, and a combination Nivolumab ipilimumab are used adjuvant therapy distant metastatic melanoma.2 The nivolumab melanoma per patient month was estimated to be USD 71,689.3 Nevertheless, efficiency these treatments is limited.4 Furthermore, metastasis can reduce effectiveness treatme...

Cancer is one of the most deadly diseases for the society and one of the most challenging diseases for the scientists all over the world to tackle with. Drugs and therapies available until now are still not effective enough for most of the cancer types and have side effects. People are, therefore looking towards traditional Ayurveda system of medicine to find out relatively safe and cost effect...

OBJECTIVE To estimate patients' elasticity of demand, willingness to pay, and consumer surplus for five high-cost specialty medications treating metastatic disease or hematologic malignancies. DATA SOURCE/STUDY SETTING Claims data from 71 private health plans from 1997 to 2005. STUDY DESIGN This is a revealed preference analysis of the demand for specialty drugs among cancer patients. We ex...

Janet is a 67-year-old woman with metastatic breast cancer. Despite having insurance, Janet has been saddled with life-altering out-of-pocket expenses from her cancer treatment. In Part I of this two-part series, we described how Janet’s struggle with out-of-pocket expenses was not unique; a growing body of evidence has detailed the negative impact of costs on insured patients receiving cancer ...